Overview
In a rapidly evolving locally advanced or metastatic urothelial cancer (Ia/mUC) treatment landscape, continuing to improve our understanding of the safety of new treatments is critical. This research builds on previously reported results showing improved overall survival and manageable safety of sacituzumab govitecan (SG) for patients who progressed on platinum-based chemotherapy and immune checkpoint inhibitor therapy, analyzing an expanded cohort with an additional year of follow-up.
Researchers found patients in the expanded cohort, most of whom received enfortumab vedotin (EV) monotherapy in the prior treatment line, saw common adverse events of diarrhea, neutropenia, and nausea. Despite these adverse events occurring frequently, observed treatment discontinuation rates were low and, overall, the observed adverse events were consistent with the known safety profile of SG.
Why this matters
Using real-world data, researchers were able to conduct the largest real-world analysis of SG use to date. The findings of this research improve our understanding of SG, especially following EV-pretreated patients, and will have the guide to help treatment decisions for patients and providers.